Skip to main content
Lyka Labs Ltd. logo

Lyka Labs Ltd. — Investor Relations & Filings

Ticker · LYKALABS ISIN · INE933A01014 LEI · 3358001RHQJBCTT1ER45 BSE.NS Manufacturing
Open in API
Filings indexed 1,205 across all filing types
Latest filing 2023-04-25 Regulatory Filings
Country IN India
Listing BSE.NS LYKALABS

About Lyka Labs Ltd.

https://www.lykalabs.com

Lyka Labs Ltd. specializes in the development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company maintains a diverse product portfolio spanning multiple therapeutic categories, including anti-infectives, dermatologicals, cardiovascular agents, and pain management. A significant area of expertise for the organization is lyophilization technology, enabling the production of high-quality injectable formulations. The company operates advanced manufacturing facilities designed to meet international quality standards, supporting its operations in both domestic and global markets. Its core activities encompass the production of various dosage forms such as tablets, capsules, ointments, and sterile injectables, with a particular focus on specialized segments like cephalosporins and critical care medications.

Recent filings

Filing Released Lang Actions
Disclosure under SEBI Takeover Regulations
Regulatory Filings Classification · 100% confidence The document text is extremely short (64 characters) and contains no substantive content, only a placeholder for an omitted picture. There is no financial data, report title, regulatory references, or any other information to classify it as a specific report type. Given the lack of content, the document does not fit any specific filing category and defaults to the fallback category for miscellaneous or non-informative filings, which is Regulatory Filings (RNS).
2023-04-25 English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ipca Laboratories Ltd & PACs
Regulatory Filings
2023-04-19 English
Outcome of Board Meeting
Regulatory Filings Classification · 100% confidence The document text is extremely short (414 characters) and consists solely of a digital signature block with no substantive content, financial data, or report information. There is no indication of any report, announcement, or filing type. Given the lack of content and the nature of the text, it does not fit any specific report category and defaults to the fallback category for miscellaneous filings.
2023-04-18 English
In Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015; the Board of Directors at its meeting held today i.e. 18th April 2023 inter ....
Regulatory Filings Classification · 100% confidence The document text is extremely short (414 characters) and consists solely of a digital signature block with no substantive content, financial data, or report information. There is no indication of any report, announcement, or filing type. Given the lack of content and the nature of the text, it does not fit any specific report category and defaults to the fallback category for miscellaneous filings.
2023-04-18 English
Pursuant to Sections 110 and 108 of the Companies Act, 2013 read with the Companies (Management and Administration) Rules, 2014, the approval of the Members was sought for the re -appointment ....
Regulatory Filings
2023-04-17 English
Shareholders meeting
Regulatory Filings
2023-04-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.